These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11995774)

  • 21. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors.
    Landén M; Thase ME
    Psychopharmacol Bull; 2006; 39(1):147-66. PubMed ID: 17065978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Premenstrual syndrome (PMS)].
    Hamatani T; Mizusawa Y; Kuji N; Yoshimura Y
    Nihon Rinsho; 2006 Jun; Suppl 2():389-94. PubMed ID: 16817427
    [No Abstract]   [Full Text] [Related]  

  • 23. Women with Premenstrual Dysphoria Lack the Seemingly Normal Premenstrual Right-Sided Relative Dominance of 5-HTP-Derived Serotonergic Activity in the Dorsolateral Prefrontal Cortices - A Possible Cause of Disabling Mood Symptoms.
    Eriksson O; Wall A; Olsson U; Marteinsdottir I; Holstad M; Ågren H; Hartvig P; Långström B; Naessén T
    PLoS One; 2016; 11(9):e0159538. PubMed ID: 27617751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.
    Steiner M; Pearlstein T; Cohen LS; Endicott J; Kornstein SG; Roberts C; Roberts DL; Yonkers K
    J Womens Health (Larchmt); 2006; 15(1):57-69. PubMed ID: 16417420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group.
    Yonkers KA; Halbreich U; Freeman E; Brown C; Endicott J; Frank E; Parry B; Pearlstein T; Severino S; Stout A; Stone A; Harrison W
    JAMA; 1997 Sep; 278(12):983-8. PubMed ID: 9307345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating premenstrual dysphoric disorder using serotonin agents.
    Lin J; Thompson DS
    J Womens Health Gend Based Med; 2001 Oct; 10(8):745-50. PubMed ID: 11703886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PMS and PMDD].
    Leminen H; Paavonen J
    Duodecim; 2013; 129(17):1756-63. PubMed ID: 24159708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An animal model of premenstrual dysphoric disorder sensitive to antidepressants.
    Schneider T; Popik P
    Curr Protoc Neurosci; 2009 Jan; Chapter 9():Unit 9.31. PubMed ID: 19170024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.
    Landén M; Eriksson O; Sundblad C; Andersch B; Naessén T; Eriksson E
    Psychopharmacology (Berl); 2001 May; 155(3):292-8. PubMed ID: 11432692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.
    Sundblad C; Hedberg MA; Eriksson E
    Neuropsychopharmacology; 1993 Sep; 9(2):133-45. PubMed ID: 8216696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD.
    Jackson C; Pearson B; Girdler S; Johnson J; Hamer RM; Killenberg S; Meltzer-Brody S
    Hum Psychopharmacol; 2015 Nov; 30(6):425-34. PubMed ID: 26193781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Premenstrual syndrome and dysphoric premenstrual syndrome].
    Alba P; Rodríguez C
    Vertex; 2014; 25(117):370-6. PubMed ID: 25545084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Premenstrual dysphoric disorder: approach and treatment].
    Bianchi-Demicheli F; Lüdicke F; Campana A
    Gynecol Obstet Fertil; 2003 Jan; 31(1):49-54. PubMed ID: 12659785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
    Steiner M; Ravindran AV; LeMelledo JM; Carter D; Huang JO; Anonychuk AM; Simpson SD
    J Clin Psychiatry; 2008 Jun; 69(6):991-8. PubMed ID: 18517289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Premenstrual dysphoric disorder. An update.
    Steiner M
    Gen Hosp Psychiatry; 1996 Jul; 18(4):244-50. PubMed ID: 8832257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and treatment of premenstrual dysphoric disorder: an update.
    Steiner M; Born L
    Int Clin Psychopharmacol; 2000 Nov; 15 Suppl 3():S5-17. PubMed ID: 11195269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder.
    Freeman EW; Rickels K; Sondheimer SJ; Polansky M; Xiao S
    Am J Psychiatry; 2004 Feb; 161(2):343-51. PubMed ID: 14754784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder.
    Roca CA; Schmidt PJ; Smith MJ; Danaceau MA; Murphy DL; Rubinow DR
    Am J Psychiatry; 2002 Nov; 159(11):1876-81. PubMed ID: 12411222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.
    Pearlstein T; Yonkers KA; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):275-82. PubMed ID: 15780697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Premenstrual syndrome and serotonin reuptake inhibitors].
    Martin-Du-Pan RC
    Rev Med Suisse; 2010 Aug; 6(258):1517. PubMed ID: 20822060
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.